Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroregeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRS drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRS ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View PTPRS Products |
| Gene Delivery | PTPRS Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression assays. |
View PTPRS Products |
| Benchmark Ab | Anti-PTPRS Recombinant Antibody Recombinant positive control derived from published therapeutic clones. |
View PTPRS Products |
| Validator | PTPRS siRNA Set For knockdown verification in functional phenotypic assays. |
View PTPRS Products |
| Related Target A | PTPRD High-homology phosphatase family member. Crucial for selectivity and off-target screening. |
View PTPRD Products |
| Related Target B | PTPRF (LAR) Co-receptor in the CSPG-mediated inhibitory pathway for axonal regeneration. |
View PTPRF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Human vs. Rodent) | Human, Mouse, and Rat recombinant PTPRS proteins available with >95% purity to support preclinical translation. |
| Subfamily selectivity screening (PTPRD/PTPRF) | Recombinant extracellular domains of PTPRD and PTPRF strictly verified by mass spectrometry to eliminate cross-reactivity. |
| Lack of positive control benchmarks | Sequence-verified biosimilar antibodies included for assay standardization. |
| Target validation false positives | Sequence-verified siRNA sets included for target knockdown validation in primary neuronal or tumor cell lines. |
Live PTPRS R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PTPRS (Receptor-type tyrosine-protein phosphatase S) is undergoing a significant paradigm shift. Historically studied as a neuronal receptor that binds chondroitin sulfate proteoglycans (CSPGs) to inhibit axonal regeneration, PTPRS is now emerging as a high-value target in both neurodegenerative diseases (such as Multiple Sclerosis and Spinal Cord Injury) and oncology. The race for PTPRS therapeutics is intensifying, with major players shifting focus from traditional small-molecule phosphatase inhibitors—which suffer from poor selectivity—to highly specific biologics, including monoclonal antibodies, peptide mimetics, and RNA therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective disruption of the extracellular CSPG-binding domain and intracellular catalytic inhibition without affecting related family members.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide Mimetics | NervGen Pharma | Spinal Cord Injury, Multiple Sclerosis, Stroke | In vitro binding inhibition assays (Requires high-purity, native-glycosylated PTPRS ECD-Fc) |
| Monoclonal Antibodies | Academic institutions, Early-stage Biotech | Oncology (Colorectal, Glioblastoma), Neuroregeneration | Epitope mapping & ligand-blocking validation (Requires human/rodent cross-reactive proteins) |
| Small Molecules | In silico-driven biotechs | Neuropathic Pain, Autoimmune Diseases | Selectivity panels (Requires recombinant active intracellular domains of PTPRS, PTPRD, and PTPRF) |